Aprea Therapeutics, Inc. (APRE)
Stock Price:
$31.46 USD
-1.38 (-4.20%)
Updated Jul 9, 2020 12:15 PM EDT - Market open
Key Info
| Market Cap |
662.39M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
20.99M |
| EPS (ttm) |
-26.67 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 9, 2020 |
| Last Price |
$31.46 |
| Previous Close |
$32.84 |
| Change ($) |
-1.38 |
| Change (%) |
-4.20% |
| Day's Open |
32.85 |
| Day's Range |
30.51 - 33.59 |
| Day's Volume |
60,692 |
| 52-Week Range |
15.10 - 53.11 |
More Stats
| Market Cap |
662.39M |
| Enterprise Value |
540.10M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
20.99M |
| Float |
12.11M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-26.67 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
763,234 |
| Short Ratio |
3.92 |
| Short % of Float |
13.14% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
6.50 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
122.29M |
| Net Cash / Share |
5.81 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-18.50% |
| ROE |
-38.95% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
1 |
| Overweight |
1 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$39.00*
(23.97% upside)
Low
30.0
Current: 31.46
High
45.0
Target: 39.00
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -29.54 | -16.49 | -15.85 |
| Net Income | -28.06 | -15.53 | -15.19 |
| Shares Outstanding | 6.00 | 1.15 | 1.15 |
| Earnings Per Share | -4.67 | -13.45 | -13.17 |
| Operating Cash Flow | -26.71 | -15.25 | -14.00 |
| Capital Expenditures | -0.03 | - | - |
| Free Cash Flow | -26.74 | -15.25 | -14.00 |
| Cash & Equivalents | 130 | 65.68 | 24.40 |
| Total Debt | 0.30 | - | - |
| Net Cash / Debt | 130 | 65.68 | 24.40 |
| Assets | 134 | 66.02 | 24.76 |
| Liabilities | 9.36 | 4.87 | 4.30 |
| Book Value | 124 | -51.44 | -35.77 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aprea Therapeutics, Inc. |
| Country |
United States |
| Employees |
13 |
| CEO |
Christian S. Schade |
Stock Information
| Ticker Symbol |
APRE |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: APRE |
Description
Aprea Therapeutics, Inc., a biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate is APR-246, a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia. The company was founded in 2006 and is headquartered in Boston, Massachusetts.